Efimosfermin Alfa (BOS-580): GSK's Once-Monthly FGF21 Analog Enters the MASH Race (July 13, 2026)
Table of Contents
A liver hormone, engineered to last a month
Fibroblast growth factor 21 (FGF21) is one of the body's own metabolic regulators. Released mainly by the liver under fasting and metabolic stress, it instructs liver, fat tissue, and brain to burn fat, sharpen insulin sensitivity, lower blood triglycerides, and quiet liver inflammation and scarring - a near-ideal profile for metabolic dysfunction-associated steatohepatitis (MASH, the fibrosing fatty-liver disease formerly called NASH). The problem is that native FGF21 disappears within hours. Efimosfermin alfa (development code BOS-580) is an engineered analog built to solve exactly that, with a half-life extended far enough to allow once-monthly subcutaneous injection - the longest dosing interval among the leading FGF21 drugs and its single biggest practical differentiator.
How it works
Mechanistically, efimosfermin does what native FGF21 does, only for much longer. The FGF21 backbone first anchors to the co-receptor beta-Klotho, then engages one of the FGF receptors (FGFR1c, FGFR2c, or FGFR3c) to trigger receptor dimerization and downstream signaling in liver, fat, and other metabolic tissues. The result is less hepatic fat production, improved insulin sensitivity, lower triglycerides, higher adiponectin, and direct anti-inflammatory and anti-fibrotic effects in the liver. That is the same pathway targeted by its two chief rivals - efruxifermin (a bivalent Fc-FGF21 fusion) and pegozafermin (a glycoPEGylated FGF21) - so the competition is less about biology than about engineering and dosing convenience.
The Phase 2 data
In a 24-week Phase 2 trial in biopsy-confirmed F2-F3 MASH, once-monthly efimosfermin delivered on both endpoints regulators care about. About 45% of treated patients achieved at least a one-stage improvement in fibrosis without worsening of MASH, and roughly 68% achieved resolution of MASH without worsening of fibrosis - both significantly better than placebo - alongside reductions in liver fat by MRI-PDFF and in liver-injury markers. An earlier Phase 2a dose-ranging study in phenotypic MASH had already shown a favorable safety profile and clear improvements in liver fat, and established that every-four-week dosing was feasible. The most common side effects across trials were gastrointestinal - diarrhea and nausea - plus increased appetite and injection-site reactions, generally mild-to-moderate and transient.
GSK's $2 billion bet
Efimosfermin originated at Boston Pharmaceuticals, and in May 2025 GSK acquired it for $1.2 billion upfront plus up to $800 million in success-based milestones - a potential ~$2 billion deal that handed GSK a Phase 3-ready, potential best-in-class entrant in steatotic liver disease. The molecule carries FDA Breakthrough Therapy designation and EMA PRIME (Priority Medicines) status for MASH, and GSK has guided to a first potential launch around 2029. For a company that had been largely on the sidelines of the metabolic-liver boom, efimosfermin is its marquee move into a field crowded with incretins and FGF21 analogs alike.
Monthly vs weekly: how it stacks up
The FGF21-for-liver race now has three clear front-runners, and dosing frequency is the sharpest line between them. Efruxifermin (Akero) and pegozafermin (89bio, now Roche/Genentech) are both dosed weekly or every two weeks and have posted strong Phase 2b fibrosis - and, for efruxifermin, compensated-cirrhosis reversal - data. Efimosfermin's pitch is that it can compete on efficacy while asking patients for just one injection a month, a meaningful advantage in a chronic, largely asymptomatic disease where adherence is hard. Its Phase 3 ZENITH program (ZENITH-1 and ZENITH-2 in F2-F3 MASH), together with a program in compensated F4 cirrhosis, will decide whether monthly convenience comes at any cost to potency.
Where it fits
Efimosfermin is a liver-directed therapy, not a weight-loss drug, and it works through a mechanism entirely distinct from the GLP-1/GIP/glucagon incretins that dominate the obesity headlines. That makes it both a standalone MASH candidate across the fibrosis spectrum and a plausible future combination partner for incretin-based agents - hitting the liver directly while the incretins drive weight loss and metabolic improvement. As always with investigational biologics: efimosfermin is available only in controlled trials, and anything sold online under its name or the code 'BOS-580' is not the clinical drug and cannot be assumed authentic, pure, or safe.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Once-monthly efimosfermin alfa (BOS-580) in MASH with F2 or F3 fibrosis: 24-week Phase 2 results - The Lancet (2025) Source
- [2] Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in phenotypic MASH: Phase 2a trial - The Lancet Gastroenterology & Hepatology (2025) Source
- [3] GSK to acquire efimosfermin, a Phase III-ready potential best-in-class medicine for steatotic liver disease - GSK (May 2025) Source
- [4] GSK's investigational liver therapy efimosfermin receives US FDA Breakthrough Therapy and EMA PRIME designations for MASH - GSK Source
- [5] A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Biopsy-confirmed F2- or F3-stage MASH - ClinicalTrials.gov (NCT07221227) Source
Related Articles
Pegozafermin (BIO89-100): The glycoPEGylated FGF21 Analog Betting on Fibrosis Reversal in MASH (July 10, 2026)
Most of the obesity headlines belong to the incretins. Pegozafermin (BIO89-100) takes a different route to the liver: a glycoPEGylated FGF21 analog engineered for a ~55-100 hour half-life and weekly-to-biweekly dosing. In Phase 2b ENLIVEN it improved fibrosis and resolved MASH at rates far above placebo - and its 2025 acquisition by Roche put a major spotlight on the FGF21 mechanism. Here's how the drug works, what the data show, and how it fits alongside efruxifermin and the incretin-based MASH contenders.
Efruxifermin (EFX): The Fc-FGF21 Fusion Betting It Can Reverse MASH Cirrhosis (July 12, 2026)
The incretins own the obesity headlines, but the liver has its own race - and it is between two FGF21 analogs. Efruxifermin (EFX) is Akero's bivalent Fc-FGF21 fusion protein, dosed once weekly, and its ambition is bigger than cutting liver fat: in Phase 2b it improved fibrosis in three-quarters of pre-cirrhotic MASH patients and reversed compensated cirrhosis in roughly two of five. Here is how the drug is built, what the HARMONY and SYMMETRY data show, and how it stacks up against pegozafermin as the Phase 3 SYNCHRONY program reads out.